RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Global Harmonization of Standards for Adaptive Clinical Trial Designs

Global Harmonization of Standards for Adaptive Clinical Trial Designs

Posted 01 August 2008 | By

Recently, important initiatives, including evaluation of adaptive design clinical trials, have been undertaken by regulatory authorities and industry associations to promote innovation in global drug development to address the slowdown in development of new medicines. In the US, the Food and Drug Administration (FDA) created the Critical Path Initiative to focus on ameliorating problems in the current drug development and approval model. One opportunity identified in the Critical Path Initiative is more-efficient trial design. This has led to the investigation of adaptive design as a way to conduct clinical trials more effectively.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.